Achilles Therapeutics plc
DelistedCIK 1830749fmd_0HB5PJ8WJNW8VV34PR4672234GManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2019 to Jun 30, 2024, 11 periods
| Line item | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|
| Research and development | 9 | 23 | 42 | 57 | 58 |
| Total operating expenses | 14 | 34 | 64 | 78 | 75 |
| Operating income | (14) | (34) | (64) | (78) | (75) |
| Other non-operating income (expense) | (0) | 1 | 3 | 7 | 6 |
| Income before taxes | (14) | (33) | (61) | (71) | (69) |
| Income tax expense | – | 0 | 0 | 0 | 0 |
| Net income from continuing operations | – | (33) | (61) | (71) | (70) |
| Net income | (14) | (33) | (61) | (71) | (70) |
| Net income to common shareholders | – | – | (61) | (71) | (70) |